New York, NY (PRWEB) April 02, 2013
Kantar Health, a leading global healthcare advisory firm, will present at the Pharma China Seminar 2013 in Princeton, N.J., on April 16, 2013.
Stephanie Hawthorne, Ph.D., Director, Clinical and Scientific Assessment, will present Oncology Treatment Trends and Implications for Future Drug Development in China. The presentation will discuss treatment outcomes among oncology patients in China and examine the implications and opportunities to biopharma companies.
Pharma China Seminar 2013 is a one-day seminar that provides insights into contemporary trends and issues of the Chinese pharmaceutical industry and marketplace today.
More information on the conference can be found at http://www.pharmachinaseminar.com/.
About Kantar Health
Kantar Health is a leading global healthcare advisory firm and trusted advisor to the worlds largest pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and marketing expertise to help clients launch products and differentiate their brands in the marketplace.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from pre-clinical development to launch, acting as catalysts to successful decision making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.